12:00 AM
 | 
Dec 21, 2015
 |  BioCentury  |  Finance

Blood money

Why Flagship picked red blood cells as a fundable modality

Flagship Ventures appears to have a thing for platform companies developing novel therapeutic modalities. The company debuted Rubius Therapeutics Inc. this month with a $25 million series A round to develop a basket of engineered red blood cells for multiple indications.

It's the third start-up with a new therapeutic modality launched this quarter, and at least the seventh among 19 companies incubated within the VC's VentureLabs group.

Rubius genetically engineers hematopoietic progenitors to produce a therapeutic protein of interest when the progenitor differentiates into an RBC. Because RBCs lack nuclei, Rubius expects its products will not have safety concerns related to unwanted differentiation...

Read the full 515 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >